
S4-31.4 – EASL Congress and ADA Scientific Sessions: Reshaping the way we think about Fatty Liver Disease
Roger Green is joined by Jörn Schattenberg to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This final conversation explores a range of topics including the role of artificial intelligence and general observations around how the different questions being asked in 2023 versus 2019 demonstrate dramatic changes in how the field understands Fatty Liver disease.